HomeCompareTDSGF vs EQR

TDSGF vs EQR: Dividend Comparison 2026

TDSGF yields 5555.56% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TDSGF wins by $173383299298071.97M in total portfolio value
10 years
TDSGF
TDSGF
● Live price
5555.56%
Share price
$0.04
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$173383299298072.00M
Annual income
$167,453,967,894,000,300,000.00
Full TDSGF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — TDSGF vs EQR

📍 TDSGF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTDSGFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TDSGF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TDSGF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TDSGF
Annual income on $10K today (after 15% tax)
$472,222.22/yr
After 10yr DRIP, annual income (after tax)
$142,335,872,709,900,260,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, TDSGF beats the other by $142,335,872,709,900,260,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TDSGF + EQR for your $10,000?

TDSGF: 50%EQR: 50%
100% EQR50/50100% TDSGF
Portfolio after 10yr
$86691649649036.02M
Annual income
$83,726,983,947,000,150,000.00/yr
Blended yield
96.58%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

TDSGF
No analyst data
Altman Z
-155.6
Piotroski
1/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TDSGF buys
0
EQR buys
0
No recent congressional trades found for TDSGF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTDSGFEQR
Forward yield5555.56%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$173383299298072.00M$47.8K
Annual income after 10y$167,453,967,894,000,300,000.00$5,475.61
Total dividends collected$172983452329089.31M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: TDSGF vs EQR ($10,000, DRIP)

YearTDSGF PortfolioTDSGF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$566,256$555,555.56$11,380$679.82+$554.9KTDSGF
2$30,006,493$29,400,599.98$13,014$837.25+$29.99MTDSGF
3$1,488,153,251$1,456,046,302.99$14,961$1,036.20+$1488.14MTDSGF
4$69,079,898,381$67,487,574,402.39$17,297$1,289.22+$69079.88MTDSGF
5$3,001,733,475,908$2,927,817,984,640.30$20,121$1,613.15+$3001733.46MTDSGF
6$122,111,548,308,987$118,899,693,489,765.72$23,561$2,030.84+$122111548.29MTDSGF
7$4,651,108,281,906,614$4,520,448,925,215,998.00$27,783$2,573.54+$4651108281.88MTDSGF
8$165,892,045,974,674,900$160,915,360,113,034,850.00$33,013$3,284.39+$165892045974.64MTDSGF
9$5,541,431,218,758,608,000$5,363,926,729,565,706,000.00$39,547$4,223.51+$5541431218758.57MTDSGF
10$173,383,299,298,072,000,000$167,453,967,894,000,300,000.00$47,791$5,475.61+$173383299298071.97MTDSGF

TDSGF vs EQR: Complete Analysis 2026

TDSGFStock

Telo Genomics Corp., a biotech company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions. It provides telomere analysis platform with diagnostic and prognostic applications; and solutions with liquid biopsies and related technologies in oncology and neurological diseases. The company's lead application is Telo-MM, a solution that provides actionable information to medical professionals in the treatment of Multiple Myeloma, a form of blood cancer. Its solutions also include TeloView, a proprietary software platform used to quantify specific features of each patient's telomeres. The company serves pathologists, clinicians, academic researchers, and drug developers. Telo Genomics Corp. has a collaboration agreement with the Mayo Clinic to validate its Telo-MM tests for multiple myeloma. The company was formerly known as 3D Signatures Inc. and changed its name to Telo Genomics Corp. in April 2019. Telo Genomics Corp. was incorporated in 2014 and is headquartered in Toronto, Canada.

Full TDSGF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this TDSGF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TDSGF vs SCHDTDSGF vs JEPITDSGF vs OTDSGF vs KOTDSGF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.